Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06364150
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-15
First Post:
2024-03-28
Brief Title:
Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction
Sponsor:
Seoul National Hospital
Organization:
Seoul National Hospital
Study Overview
Official Title:
Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MAGICcell6
Brief Summary:
This study will evaluate the efficacy and safety of Therapeutic Use of Autologous-Primed Autologous Peripheral Blood Stem Cell Treatment for Myocardial Regeneration in Acute Myocardial Infarction
Detailed Description:
Patients diagnosed with acute myocardial infarction will receive percutaneous coronary intervention to the culprit coronary artery according to standard procedures For peripheral blood stem cell mobilization Granulocyte colony-stimulating factor G-CSF and erythropoietin EPO will be injected for a total of 4 days followed by collection of mobilized peripheral blood stem cell mobPBSC via apheresis In ex-vivo setting mobPBSC will be primed with angiopoietin 1 Ang1 for 1 hour A total of 2 X109 Ang1 primed mobPBSC will be injected to the culprit artery
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None